Quanterix Corp

QTRX is in an early-stage consolidation following a clear LH/LL decline, with a recent Momentum Breakout signaling renewed demand. However, price is extremely overbought and extended above the short-term EMAs, suggesting timing is unfavorable. Medium-term directional bias is bullish, but execution should be deferred until pullbacks into the 9/21 EMA confluence and prior resistance-turned-support.

• ↑Q1 ’26 revenue reached $36.4M, up 20% YoY on diagnostics deals
• ↑Diagnostics sales jumped to $2.9M from $1.6M, signaling market traction
• ↓Organic revenue slid 21% as instrument orders underperformed